London, United Kingdom —
Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.
Riad Mishlawi, Chief Executive Officer of Hikma, said: “The good momentum during the first half has continued, enabling us to upgrade full year guidance in two of our three businesses. Our Branded business is performing exceptionally well on an underlying basis and our Generics business has seen key products continuing to drive better-than-expected performance. In Injectables, we are seeing solid growth, supported by a good performance in MENA and Europe, and we have continued to invest across all our regions to expand manufacturing capacity and build our pipeline. Overall, the Group is making excellent progress and we are on track to deliver very strong earnings growth for the full year.”
Injectables
We continue to see solid growth in our global Injectables business. In North America, while we have continued to see strong customer demand for our broad product portfolio and a good contribution from new product launches in the second half, growth has been lower than expected due to short-term supply and capacity constraints. These constraints are easing as newly installed high-speed manufacturing lines in both our Cherry Hill and Portugal facilities are becoming fully operational and we are well-positioned to meet demand in 2024.
Our MENA business is performing very well, with launches driving growth and offsetting the loss of sales in Sudan. In Europe, we are delivering strong growth in Germany and Italy and are gradually building share in Spain, France, and the UK.
We are continuing to invest extensively across our Injectables business to expand our portfolio and manufacturing capacity. We are making good progress on our new facilities in Morocco and Algeria and are gradually advancing our 503B sterile compounding business in the US.
We now expect full year revenue growth and core operating margin to be at the lower end of our guidance range of 7% to 9% and 36% to 37%, respectively. This takes into consideration the closure of our Sudanese manufacturing facility, investment in our compounding business and the short-term capacity constraints in the US.
Branded
Our Branded business continues to see strong demand. Medicines used to treat chronic illnesses are driving growth across our key MENA markets, offsetting the combined headwinds of the devaluation of the Egyptian Pound and the closure of our Sudanese manufacturing facility. Leveraging our local manufacturing presence and strong commercial teams, we continue to launch new products, including first-to-market generics and innovative in-licenced products. Our teams are focused on driving efficiencies at our facilities across the region, and this, combined with a favourable product mix, is leading to improved profitability.
We continue to expect Branded revenue to grow in the mid-to-high single digits in constant currency. On a reported basis, assuming no further adverse currency movements, we continue to expect Branded revenue to be in line with 2022, offsetting headwinds resulting from the devaluation of the Egyptian Pound and the closure of our Sudan operations. Due to our strong performance and focus on efficiencies, we now expect core operating margin to expand to around 23% for the full year.
Generics
Our Generics business continues to have an excellent year, as we benefit from favourable market dynamics across our base business and a stronger than expected revenue contribution from our authorised generic of sodium oxybate.
We are pleased with the efforts we are making to utilise spare capacity at our Columbus plant for contract manufacturing and are making good progress with our specialty products.
We now expect 2023 revenue in the range of $920 million to $940 million and core operating margin of around 20%, up from previous guidance of close to 30% growth and margins of 18% to 20%.
